You are about to leave doptelethcp.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
You are about to leave doptelethcp.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
This information is intended for healthcare professionals in the United States.
Are you a healthcare professional?
Yes
NoDiscover the Copay Assistance Program
Terms and Conditions
DOPTELET IS THE FASTEST-GROWING TPO-RA1**
Based on year-over-year financial market growth data for TPO-RAs from fiscal year 2021 compared to fiscal year 2022.1
Reference: 1. Data on file. TPO-RA Market Growth. 2023: Sobi, Inc.
DOPTELET NOW HAS PARITY ACCESS WITH ELTROMBOPAG AT SOME OF THE LARGEST COMMERCIAL PLANS1
Use our look-up tool to see if your commercial plan is eligible for Doptelet.
Reference: 1. Data on file. CAM Conversion Guide. 2022: Sobi, Inc.
The recommended starting dose is 20 mg once daily with food and dose adjust as needed.
Disclaimer: The minimum dose on Doptelet is 20 mg once weekly and the maximum is 40 mg once daily.
Dose adjustments may be needed based on platelet response and for patients taking moderate or strong dual inducers or inhibitors of CYP2C9 and CYP3A4.*
Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 20 mg 3 times a week; start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 40 mg once daily.1,2 Please see Full Prescribing Information for additional information on dose adjustments.
After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50×109/L has been achieved, and then obtain platelet counts monthly thereafter.
Want more information on dosing & titration?
Answer these 3 questions:
I’m looking for dosing recommendations for:
Is your patient taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4?
What is your patient’s platelet count?
Platelet count (x109/L)
My patient is taking:
My patient is currently taking Doptelet at this dosage strength:
Recommended starting dose:
20 mg once daily.
Doptelet is the only oral TPO-RA of its kind that your patients can take based on their schedule.1
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
This website uses cookies. By continuing to use this website, you consent to our use of these cookies.